Unknown

Dataset Information

0

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.


ABSTRACT: The advent of engineered T cells as a form of immunotherapy marks the beginning of a new era in medicine, providing a transformative way to combat complex diseases such as cancer. Following FDA approval of CAR T cells directed against the CD19 protein for the treatment of acute lymphoblastic leukemia and diffuse large B cell lymphoma, CAR T cells are poised to enter mainstream oncology. Despite this success, a number of patients are unable to receive this therapy due to inadequate T cell numbers or rapid disease progression. Furthermore, lack of response to CAR T cell treatment is due in some cases to intrinsic autologous T cell defects and/or the inability of these cells to function optimally in a strongly immunosuppressive tumor microenvironment. We describe recent efforts to overcome these limitations using CRISPR/Cas9 technology, with the goal of enhancing potency and increasing the availability of CAR-based therapies. We further discuss issues related to the efficiency/scalability of CRISPR/Cas9-mediated genome editing in CAR T cells and safety considerations. By combining the tools of synthetic biology such as CARs and CRISPR/Cas9, we have an unprecedented opportunity to optimally program T cells and improve adoptive immunotherapy for most, if not all future patients.

SUBMITTER: Salas-Mckee J 

PROVIDER: S-EPMC6605860 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.

Salas-Mckee January J   Kong Weimin W   Gladney Whitney L WL   Jadlowsky Julie K JK   Plesa Gabriela G   Davis Megan M MM   Fraietta Joseph A JA  

Human vaccines & immunotherapeutics 20190402 5


The advent of engineered T cells as a form of immunotherapy marks the beginning of a new era in medicine, providing a transformative way to combat complex diseases such as cancer. Following FDA approval of CAR T cells directed against the CD19 protein for the treatment of acute lymphoblastic leukemia and diffuse large B cell lymphoma, CAR T cells are poised to enter mainstream oncology. Despite this success, a number of patients are unable to receive this therapy due to inadequate T cell numbers  ...[more]

Similar Datasets

| S-EPMC7035593 | biostudies-literature
| S-EPMC4759811 | biostudies-other
| S-EPMC10658519 | biostudies-literature
| S-EPMC6398936 | biostudies-literature
| S-EPMC5852178 | biostudies-literature
| S-EPMC6469419 | biostudies-other
| S-EPMC6764340 | biostudies-literature
| S-EPMC9176214 | biostudies-literature
| S-EPMC4302896 | biostudies-other
| S-EPMC5116081 | biostudies-other